---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-034049"
form_type: "8-K"
ticker: "MNPR"
cik: "0001645469"
company_name: "Monopar Therapeutics"
filed_at: "2024-11-08T23:59:59+00:00"
generated_at: "2026-05-30T02:50:51.186865+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Monopar reports Q3 net loss $1.3M; in-licensed Wilson disease drug ALXN-1840; raised $17.7M

## Summary
- Net loss Q3 2024 $1.3M ($0.37/share) vs $2.0M ($0.69/share) Q3 2023.
- Exclusive license from Alexion for ALXN-1840 (Wilson disease, Phase 3 completed); planning FDA discussions.
- MNPR-101-Lu Phase 1a therapy trial active and enrolling in Australia; MNPR-101-Zr imaging trial shows tumor uptake.
- Completed public offering Oct 30, 2024: 1,181,540 shares at $16.25/sh, net $17.7M.
- Cash $6.0M at Sept 30; pro forma runway into first half 2026.

## SEC filing metadata
- accession: 0001437749-24-034049
- form_type: 8-K
- ticker: MNPR
- cik: 0001645469
- company_name: Monopar Therapeutics
- filed_at: 2024-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645469/000143774924034049/0001437749-24-034049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645469/000143774924034049/mnpr20241107_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-034049
- JSON: https://secwatch.observer/filing/0001437749-24-034049.json
- Plain text: https://secwatch.observer/filing/0001437749-24-034049.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.